Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

(Bloomberg) -- Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Leerink lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $19 from $20 and keeps an Outperform rating on the shares. The ...

Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB; HKEX: 9688), an innovative, commercial-stage biopharmaceutical ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb Company - ...

Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Xencor in a ...

Stock analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for shares of Zymeworks in a ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...